Large holder notice
Open the filing on sec.gov
Jade Biosciences, Inc. (JBIO)
Nasdaq: JBIO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2020
The companyfiscal 2025, as filed
Revenuen/a
Net income-$127M-83.0%
Earnings per share$-3.19-30.7%
Operating cash flow-$94.7M-33.0%
Cash$88.4M+27.5%
Debtn/a
Shareholders’ equity$333M+810.5%
Shares, diluted31.4M+9.7%
Return on equity-38.3%
The recordfrom its filings
Filings in 202665
Newest filingOct 28 · SCHEDULE 13G
Annual reportMar 6, 2026
Quarterly reportAug 10, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted6
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$153MCash from operations -$124Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Large holder notice
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.